Abstract
The aim of the present study was to compare the effects of three preferential (BRL 37344, SR 58611, CL 316 243) and a partial (CGP 12177) β-adrenoceptor (β3-AR) agonists on the contractility of ventricular strips sampled from various mammalian species including humans. In the human heart, all β3-AR agonists tested decreased contractility by 40 to 60% below control with an order of potency: BRL 37344 > CL 316 243 = SR 58611 ≫ CGP 12177. In the dog, the negative inotropic effects produced by β3-AR stimulation were less pronounced than in humans, ≈30% below control. The order of potency of β3-AR agonists was CGP 12177 > BRL 37344 = SR 58611 ≫ CL 316 243; i.e., very different from that observed in humans. In rat, only BRL 37344 was efficient to decrease contractility. In guinea pig, only CL 316 243 significantly reduced peak tension. In both species, the reduction in peak tension did not exceed 20 to 30%. Finally, in the ferret, none of the agonists tested induced a negative inotropic effect. In dog, the negative inotropic effects of CGP 12177 were not modified by nadolol, but were abolished by bupranolol, a β1–3-AR. β3-AR transcripts were detected in the dog but not in the rat ventricle by using a reverse transcription-polymerase chain reaction assay. We conclude that cardiac negative inotropic effects related to β3-AR agonist stimulation vary markedly depending on the species. A comparable interspecies variation previously has been reported concerning the lipolytic effects of β3-AR agonist stimulation. Our study demonstrates that the pharmacological profile of a β3-AR agonist on the human myocardium cannot be extrapolated from usual animal models.
Footnotes
-
Send reprint requests to: Dr. Chantal Gauthier, Laboratoire de Physiopathologie et Pharmacologie Cellulaires et Moléculaires, Institut National de la Santé et de la Recherche Médicale, CJF 96–01, Hôtel Dieu, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1, France. E-mail:chantal.gauthier{at}sante.univ-nantes.fr
-
↵1 This work was supported by grants from Institut National de la Santé et de la Recherche Médicale, the Association de Recherche en Physiologie et Pharmacologie (ARPP), and the Fédération Française de Cardiologie.
- Abbreviations:
- AR
- adrenoceptor
- CGP 12177
- 4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2-one
- SR 58611
- (N[2s)7-carb-ethoxymethoxy-1,2,3,4-tetra-hydronaphth]-(2r)-2-hydroxy-2(3-chlorophenyl) ethamine hydrochloride
- CL 316 243
- 5-(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]-amino}propyl)-1,3-benzodioxole-2,2-dicarboxylate
- BRL 37344
- 4-[−[2-hydroxy-(3-chlorophenyl)ethyl-amino]propyl]phenoxyacetate
- RT-PCR
- reverse transcription-polymerase chain reaction
- Received May 26, 1998.
- Accepted March 29, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|